A method of manufacturing a mono-layer tablet comprising a pharmaceutical composition comprises tabletting of one or more final blends in form of granules, wherein the pharmaceutical composition comprises a SGLT-2 inhibitor, a partner drug, and one or more pharmaceutical excipients, wherein the partner drug is metformin hydrochloride, and wherein the SGLT-2 inhibitor is 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-( -tetrahydrofuran-3-yloxy)-benzyl]-benzene, wherein the amount of the SGLT2 inhibitor is from 1 to 25 mg, and wherein the unit dosage strength of metformin hydrochloride is from 100 mg to 2000 mg, wherein the granules are prepared according to a granulation process comprising i.) combining (e.g. dissolving or dispersing) a binder and the SGLT-2 inhibitor in a solvent or mixture of solvents such as purified water at ambient temperature to produce a granulation liquid; ii.) blending metformin HCl and a filler in a suitable mixer (e.g. fluid-bed granulator) to produce a pre-mix, wherein the SGLT-2 inhibitor is dispersed in the granulation liquid and is absent in the pre-mix; iii.) spraying the granulation-liquid into the pre-mix and granulating the mixture for example in a fluid-bed granulator, preferably under dry condition; iv.) drying the granulate, e.g. at about 70° C inlet air temperature until the desired loss on drying value in the range of 1-3 %, for example 0.8-2 %, is obtained; v.) delumping the dried granulate for example by sieving through a sieve with a mesh size of 0.5 to 1.0 mm; vi.) blending the sieved granulate and preferably sieved glidant in a suitable blender; vii.) adding preferably sieved lubricant to the granulate for final blending for example in the free-fall blender. wherein the pharmaceutical composition comprises a SGLT-2 inhibitor, a partner drug, and one or more pharmaceutical excipients, wherein the partner drug is metformin hydrochloride, and wherein the SGLT-2 inhibitor is 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-( -tetrahydrofuran-3-yloxy)-benzyl]-benzene, wherein the amount of the SGLT2 inhibitor is from 1 to 25 mg, and wherein the unit dosage strength of metformin hydrochloride is from 100 mg to 2000 mg, wherein the granules are prepared according to a granulation process comprising i.) combining (e.g. dissolving or dispersing) a binder and the SGLT-2 inhibitor in a solvent or mixture of solvents such as purified water at ambient temperature to produce a granulation liquid; ii.) blending metformin HCl and a filler in a suitable mixer (e.g. fluid-bed granulator) to produce a pre-mix, wherein the SGLT-2 inhibitor is dispersed in the granulation liquid and is absent in the pre-mix; iii.) spraying the granulation-liquid into the pre-mix and granulating the mixture for example in a fluid-bed granulator, preferably under dry condition; iv.) drying the granulate, e.g. at about 70° C inlet air temperature until the desired loss on drying value in the range of 1-3 %, for example 0.8-2 %, is obtained; v.) delumping the dried granulate for example by sieving through a sieve with a mesh size of 0.5 to 1.0 mm; vi.) blending the sieved granulate and preferably sieved glidant in a suitable blender; vii.) adding preferably sieved lubricant to the granulate for final blending for example in the free-fall blender. i.) combining (e.g. dissolving or dispersing) a binder and the SGLT-2 inhibitor in a solvent or mixture of solvents such as purified water at ambient temperature to produce a granulation liquid; ii.) blending metformin HCl and a filler in a suitable mixer (e.g. fluid-bed granulator) to produce a pre-mix, wherein the SGLT-2 inhibitor is dispersed in the granulation liquid and is absent in the pre-mix; iii.) spraying the granulation-liquid into the pre-mix and granulating the mixture for example in a fluid-bed granulator, preferably under dry condition; iv.) drying the granulate, e.g. at about 70° C inlet air temperature until the desired loss on drying value in the range of 1-3 %, for example 0.8-2 %, is obtained; v.) delumping the dried granulate for example by sieving through a sieve with a mesh size of 0.5 to 1.0 mm; vi.) blending the sieved granulate and preferably sieved glidant in a suitable blender; vii.) adding preferably sieved lubricant to the granulate for final blending for example in the free-fall blender.